Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients

Inclusion Criteria:

1. Signed informed consent prior to trial participation.
2. HIV-1 infected males or females >= 18 years of age.
3. No previous ARV therapy.
4. Any CD4+ T lymphocyte count < 500 cells / µl.
5. HIV-1 viral load >= 5000 copies/mL at screening.
6. Screening laboratory values that indicate adequate baseline organ function.
7. A prior AIDS defining event is acceptable as long as it has resolved or the subject has been on stable treatment (e.g. opportunistic infection; no ARV) for at least 2 weeks before screening

Exclusion criteria:

1. Female patients of child-bearing potential who:

   • have a positive serum pregnancy test at screening or during the study,
   • are breast feeding,
   • are planning to become pregnant

2. Use of investigational medications within 30 days before study entry or during the trial